Current Report Filing (8-k)
October 26 2022 - 1:59PM
Edgar (US Regulatory)
0000727346
false
0000727346
2022-10-25
2022-10-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 25, 2022
SELECTIS
HEALTH, INC.
(Exact
Name of Registrant as Specified in its Charter)
Utah |
|
0-15415 |
|
87-0340206 |
(State
or other jurisdiction
of
incorporation) |
|
Commission
FileNumber |
|
(I.R.S.
Employer
Identification
number) |
8480
E. Orchard Road, Suite 4900, Greenwood Village, CO 80111
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (720) 680-0808
|
|
|
|
(Former
name or former address, if changed since last report) | |
☐ |
Written
communications pursuant to Rule 425 under the Securities Act |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each Class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
N/A |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
ITEM
7.01 REGULATION FD DISCLOSURE
The
Company presented its October 25, 2022 investor presentation to the LD Micro Main Event Conference VIII on October 25, 2022. A copy of
the presentation is filed herewith as Exhibit 99.1.
The
information in this Current Report on Form 8-K furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to liability under that section, and they shall not be deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. By filing this Current
Report on Form 8-K and furnishing this information pursuant to Item 7.01, the Company makes no admission as to the materiality of any
information in this Current Report on Form 8-K, including Exhibit 99.1, that is required to be disclosed solely by Regulation FD.
ITEM
9.01 EXHIBITS
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
|
|
Selectis
Health, Inc. |
|
|
|
(Registrant) |
|
|
|
|
Dated: |
October
26, 2022 |
|
/s/
Lance Baller |
|
|
|
Lance
Baller, CEO |
Selectis Health (PK) (USOTC:GBCS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Selectis Health (PK) (USOTC:GBCS)
Historical Stock Chart
From Jul 2023 to Jul 2024